Nonviral cryoglobulinemic vasculitis: an updated review for clinical practice

Abstract

The clinical spectrum of cryoglobulinemic-associated diseases is broad and heterogeneous, with manifestations ranging from mild symptoms (e.g., isolated palpable purpura) to organ- and life-threatening involvement (e.g., membranoproliferative glomerulonephritis). Cryoglobulins are classified into three types. Type I cryoglobulinemia consists of one monoclonal immunoglobulin (Ig) and is practically always associated with B-cell lymphoproliferative disorders. In contrast, type II/III (mixed) cryoglobulinemia is composed of mono- or polyclonal IgM with rheumatoid factor activity bound to polyclonal IgG. Since the introduction of more efficient therapies for chronic hepatitis C virus (HCV), other diseases such as systemic autoimmune disorders and lymphoproliferative neoplasms have been established as the main causes of mixed cryoglobulinemic vasculitis. The pathogenesis of cryoglobulinemic vasculitis is a complex multifactorial process that involves B-cell aberrant lymphoproliferation and autoantibody production. Therefore, treatment of these patients may involve not only measures aimed to mitigate the severity of clinical manifestation but also those that address the associated underlying disease responsible for Ig production. The treatment of patients with type I cryoglobulinemia is primarily focused on controlling B lymphocyte clones responsible for cryoglobulin production, mostly with chemotherapy drugs. Treatment of mixed cryoglobulinemia syndrome is based on rituximab plus glucocorticoids, which induces remission in the vast majority of cases. In the rare patients that do not respond to rituximab administration, potential rescue approaches include alkylating agents, biologic therapies, conventional immunosuppression, and plasma exchange, although with partial efficacy. This narrative review explores the etiology, pathophysiology, clinical manifestations, treatment, and prognosis of nonviral cryoglobulinemic disease. A special focus is placed on the treatment of type I cryoglobulinemia and rituximab-resistant non-HCV cryoglobulinemic vasculitis.

Keywords

Vasculitis / cryoglobulinemia / rituximab

References

[1] Desbois AC,Saadoun D.Cryoglobulinemia: an update in 2019.Joint Bone Spine2019;86:707-13

[2] Jennette JC,Bacon PA.2012 revised international chapel hill consensus conference nomenclature of vasculitides.Arthritis Rheum2013;65:1-11

[3] Muchtar E,Gertz MA.How I treat cryoglobulinemia.Blood2017;129:289-98

[4] Brouet JC,Danon F,Seligmann M.Biologic and clinical significance of cryoglobulins. A report of 86 cases.Am J Med1974;57:775-88

[5] Roccatello D,Ramos-Casals M.Cryoglobulinaemia.Nat Rev Dis Primers2018;4:11

[6] Kolopp-Sarda MN.Cryoglobulins: an update on detection, mechanisms and clinical contribution.Autoimmun Rev2018;17:457-64

[7] Kolopp-Sarda MN,Miossec P.Cryoglobulins today: detection and immunologic characteristics of 1,675 positive samples from 13,439 patients obtained over six years.Arthritis Rheumatol2019;71:1904-12

[8] Boleto G,Musset L.Cryoglobulinemia after the era of chronic hepatitis C infection.Semin Arthritis Rheum2020;50:695-700

[9] Desbois AC,Saadoun D.Cryoglobulinemia vasculitis: how to handle.Curr Opin Rheumatol2017;29:343-7

[10] Terrier B,Lacraz A.Non HCV-related infectious cryoglobulinemia vasculitis: results from the french nationwide CryoVas survey and systematic review of the literature.J Autoimmun2015;65:74-81

[11] Pietrogrande M,Zignego AL.Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.Autoimmun Rev2011;10:444-54

[12] Quartuccio L,Scirè CA.Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian study group of cryoglobulinemia (GISC).Clin Rheumatol2023;42:359-70 PMCID:PMC9873783

[13] Retamozo S,Bosch X,Ramos-Casals M.Cryoglobulinemic disease.Oncology2013;27:1098-105

[14] Retamozo S,Bosch X.Life-Threatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients.Medicine2013;92:273-84 PMCID:PMC4553974

[15] Ostojic P.Managing refractory cryoglobulinemic vasculitis: challenges and solutions.J Inflamm Res2017;10:49-54 PMCID:PMC5428757

[16] Harel S,Jahn I.Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases.Br J Haematol2015;168:671-8

[17] Sidana S,Dispenzieri A.Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia.Am J Hematol2017;92:668-73 PMCID:PMC5579826

[18] Terrier B,Kahn JE.The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases.Medicine2013;92:61-8 PMCID:PMC4553985

[19] Fuentes A,Burgos PI.Understanding the cryoglobulinemias.Curr Rheumatol Rep2019;21:60

[20] Retamozo S,Ramos-Casals M.Cryoglobulinemia.Med Clin2022;158:478-87

[21] Trejo O,García-Carrasco M.Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center.Medicine2001;80:252-62

[22] Néel A,Decaux O.Long-term outcome of monoclonal (type 1) cryoglobulinemia.Am J Hematol2014;89:156-61

[23] Zhang LL,Shen KN.Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients.Ann Hematol2020;99:1735-40

[24] Athanassiou P,Weston J,Kontomerkos T.Type 1 cryoglobulinaemia associated with a thymic tumour: successful treatment with plasma exchange.Br J Rheumatol1995;34:285-9

[25] Dammacco F,Vacca A.The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements.Clin Exp Med2023;23:255-72 PMCID:PMC8960698

[26] Ramos-Casals M,Cid MC.The cryoglobulinaemias.Lancet2012;379:348-60

[27] Ferri C,Longombardo G.Association between hepatitis C virus and mixed cryoglobulinemia [see comment].Clin Exp Rheumatol1991;9:621-4

[28] Retamozo S,Quartuccio L.Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients.Rheumatology2016;55:1443-51

[29] Quartuccio L,Priori R.GRISS GroupCryoglobulinemia in Sjögren syndrome: a disease subset that links higher systemic disease activity, autoimmunity, and local B cell proliferation in mucosa-associated lymphoid tissue.J Rheumatol2017;44:1179-83

[30] Tzioufas AG,Costello R,Papadopoulos NM.Cryoglobulinemia in autoimmune rheumatic diseases. Evidence of circulating monoclonal cryoglobulins in patients with primary Sjögren's syndrome.Arthritis Rheum1986;29:1098-104

[31] García-Carrasco M,Cervera R.Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients.Semin Arthritis Rheum2001;30:366-73

[32] Perlemuter G,Sbai A.Hepatitis C virus infection in systemic lupus erythematosus: a case-control study.J Rheumatol2003;30:1473-8

[33] Brito-Zerón P,Bootsma H.Sjögren syndrome.Nat Rev Dis Primers2016;2:16047

[34] Giuggioli D,Colaci M,Antonelli A.Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature.Autoimmun Rev2013;12:1058-63

[35] Galli M,Saccardo F.HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian group for the study of cryoglobulinaemias (GISC).Clin Exp Rheumatol2017;35:67-76

[36] Ferri C,Giuggioli D.Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients.Semin Arthritis Rheum2004;33:355-74

[37] Pasquet F,Macgregor B.Safety and efficacy of rituximab treatment for vasculitis in hepatitis B virus-associated type II cryoglobulinemia: a case report.J Med Case Rep2012;6:39 PMCID:PMC3292813

[38] Sawabe T,Imafuku S,Arima J.Remission of hepatitis B virus-related vasculitis with lamivudine.Ann Intern Med2004;140:672-3

[39] Kawakami T,Mizoguchi M,Yamazaki M.Remission of hepatitis B virus-related cryoglobulinemic vasculitis with entecavir.Ann Intern Med2008;149:911-2

[40] Enomoto M,Ishii M,Kawada N.Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis.Ann Intern Med2008;149:912-3

[41] Mazzaro C,Visentini M.Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: a review of the literature.Front Oncol2023;13:1095780 PMCID:PMC9941626

[42] Mazzaro C,Gragnani L.Hepatitis B virus-related cryoglobulinemic vasculitis: review of the literature and long-term follow-up analysis of 18 patients treated with nucleos(t)ide analogues from the Italian study group of cryoglobulinemia (GISC).Viruses2021;13:1032 PMCID:PMC8226459

[43] Mazzaro C,Visentini M.Hepatitis B virus-related cryogobulinemic vasculitis. The role of antiviral nucleot(s)ide analogues: a review.J Intern Med2019;286:290-8

[44] Scotto G,Saracino A.Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection.J Infect2006;52:294-9

[45] Lunel F,Cacoub P.Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage.Gastroenterology1994;106:1291-300

[46] Delgado S,Gotuzzo E.Mixed cryoglobulinemia due to brucellosis.Clin Infect Dis2008;47:435-6

[47] Padrón Romero M,Ahijado Hormigos FJ.Membranoproliferative glomerulonephritis and mixed cryoglobulinemia as a form of presentation of visceral leishmaniasis.Am J Case Rep2020;21:e921445 PMCID:PMC7274496

[48] Arora S,Regmi N.Cryoglobulinemia in a patient with chronic lymphocytic leukemia - a case report and review of literature of renal involvement in CLL.Blood Cells Mol Dis2016;60:7-11

[49] Lenzi M,Mantovani V.Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia.Blood1998;91:2062-6

[50] Zignego AL,Cacoub P.Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis.Genes Immun2014;15:500-5 PMCID:PMC4208981

[51] Gragnani L,Piluso A.Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame?.World J Gastroenterol2013;19:8910-5 PMCID:PMC3870543

[52] De Re V,De Zorzi M.Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.PLoS One2015;10:e0117420 PMCID:PMC4336327

[53] Chang ML,Chen SC.Genetic association of hepatitis C-related mixed cryoglobulinemia: a 10-year prospective study of asians treated with antivirals.Viruses2021;13:464 PMCID:PMC7998980

[54] Crowley JJ,Schrohenloher RE.Incidence of three cross-reactive idiotypes on human rheumatoid factor paraproteins.J Immunol1988;140:3411-8

[55] Kunkel HG,Joslin FG,Capra JD.Cross-idiotypic specificity among monoclonal IgM proteins with anti- -globulin activity.J Exp Med1973;137:331-42 PMCID:PMC2139491

[56] Shokri F,Maziak BR.Lymphoproliferation in primary Sjögren's syndrome. Evidence of selective expansion of a B cell subset characterized by the expression of cross-reactive idiotypes.Arthritis Rheum1993;36:1128-36

[57] Tzioufas AG,Skopouli FN.Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome.Arthritis Rheum1996;39:767-72

[58] Muramatsu M,Fagarasan S,Shinkai Y.Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.Cell2000;102:553-63

[59] De Vita S,Sansonno D.Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis.Hepatology2000;31:182-9

[60] Isnardi I,Menard L.Complement receptor 2/CD21^- human naive B cells contain mostly autoreactive unresponsive clones.Blood2010;115:5026-36 PMCID:PMC3373152

[61] Ivanovski M,Pozzato G.Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas.Blood1998;91:2433-42

[62] Flint M,Maidens CM.Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein.J Virol1999;73:6782-90 PMCID:PMC112763

[63] Yagnik AT,Meola A.A model for the hepatitis C virus envelope glycoprotein E2.Proteins2000;40:355-66

[64] Sene D,Thibault V.Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus.J Rheumatol2004;31:2199-206

[65] Sansonno D,Iacobelli AR,Distasi M.Hepatitis C virus infection and clonal B-cell expansion.Clin Exp Rheumatol1996;14:S45-50

[66] Couronné L,Roulland S.From hepatitis C virus infection to B-cell lymphoma.Ann Oncol2018;29:92-100

[67] Agnello V,Abel G.The association of hepatitis C virus infection with monoclonal rheumatoid factors bearing the WA cross-idiotype: implications for the etiopathogenesis and therapy of mixed cryoglobulinemia.Clin Exp Rheumatol1995;13:S101-4

[68] Dammacco F.Mixed cryoglobulinemia as a model of systemic vasculitis.Clin Rev Allergy Immunol1997;15:97-119

[69] Agnello V.The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection.Springer Semin Immunopathol1997;19:111-29

[70] Charles ED,Marukian S.Clonal expansion of immunoglobulin M⁺CD27⁺ B cells in HCV-associated mixed cryoglobulinemia.Blood2008;111:1344-56 PMCID:PMC2214737

[71] Perkins GB,Coates PT.Going rogue: how autoantibodies become pathogenic.Kidney Int2021;99:800-2

[72] Singh M,Wang JJ.Lymphoma driver mutations in the pathogenic evolution of an iconic human autoantibody.Cell2020;180:878-94

[73] Dustin LB.Flying under the radar: the immunobiology of hepatitis C.Annu Rev Immunol2007;25:71-99

[74] Merlini G.Dangerous small B-cell clones.Blood2006;108:2520-30

[75] Alba MA,Falk RJ.Chapter 65 - necrotizing arteritis and small-vessel vasculitis. In: Rose NR, Mackay IR, editors. The autoimmune diseases. Cambridge: Academic Press; 2020, pp. 1285-311.

[76] Kolopp-Sarda MN.Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis.Curr Opin Rheumatol2021;33:1-7

[77] Hall CG.Reversible self-association of a human myeloma protein. Thermodynamics and relevance to viscosity effects and solubility.Biochemistry1984;23:5123-9

[78] Kochwa S,Brownell M.Aggregation of IgG globulin in vivo. II. Physicochemical properties of the isolated protein.Biochemistry1966;5:277-85

[79] Erickson BW,Wang AC.Molecular basis for the temperature-dependent insolubility of cryoglobulins - XI. Sequence comparison of the heavy-chain variable regions of the human cryoimmunoglobulins McE and Hil by metric analysis.Mol Immunol1982;19:357-65

[80] Gerber-Jenson B,Kehoe JM,Erickson BW.Molecular basis for the temperature-dependent insolubility of cryoglobulins. X. The amino acid sequence of the heavy chain variable region of McE.J Immunol1981;126:1212-6

[81] Zinneman HH,Seal US.Some biochemical properties of a cryomacroglobulin.Clin Chim Acta1973;43:91-9

[82] Konieczny L.Agreggation and precipitation in cryoglobulin.Bull Soc Chim Biol1970;52:365-76

[83] Middaugh CR,Hurvitz A,Scheffel C.Physicochemical characterization of six monoclonal cryoimmunoglobulins: possible basis for cold-dependent insolubility.Proc Natl Acad Sci USA1978;75:3440-4 PMCID:PMC392793

[84] Andersen BR,Schmid FR,Hartz WH.Biological and physical properties of a human m-cryoglobulin and its monomer subunit.Clin Exp Immunol1971;9:795-807 PMCID:PMC1713132

[85] Ramos-Casals M,García-Carrasco M,Font J.Mixed cryoglobulinemia: new concepts.Lupus2000;9:83-91

[86] Lawson EQ,Trautman PA,Middaugh CR.Kinetics of the precipitation of cryoimmunoglobulins.Mol Immunol1987;24:897-905

[87] Scoville CD,Lippert JL.Study of the kinetic and structural properties of a monoclonal immunoglobulin G cryoglobulin.J Biol Chem1980;255:5847-52

[88] Wang Y,Hideshima T.Pathological crystallization of human immunoglobulins.Proc Natl Acad Sci USA2012;109:13359-61 PMCID:PMC3421172

[89] Podell DN,Maniloff J.Characterization of monoclonal IgG cryoglobulins: fine-structural and morphological analysis.Blood1987;69:677-81

[90] Vallas V,Raison RL,Ramsland PA.Dissimilar aggregation processes govern precipitation and gelation of human IgM cryoglobulins.J Mol Recognit2007;20:90-6

[91] Brandau DT,Steadman BL,Middaugh CR.The temperature-dependent stoichiometry of mixed cryoimmunoglobulins.J Biol Chem1986;261:16385-91

[92] Ng YC.Clearance of cryoglobulins in man.Springer Semin Immunopathol1988;10:75-89

[93] Ferri C,Pileri SA.Cryoglobulins.J Clin Pathol2002;55:4-13 PMCID:PMC1769573

[94] Sansonno D,Ghebrehiwet B.Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage.J Immunol2009;183:6013-20 PMCID:PMC2794553

[95] Menegatti E,Oddone V.Immunogenetics of complement in mixed cryoglobulinaemia.Clin Exp Rheumatol2016;34:S12-5

[96] Karras A,Droz D.Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3 kappa cryoglobulin.Am J Kidney Dis2002;40:1091-6

[97] Zaidan M,Pozdzik A.CryoVas study groupSpectrum and prognosis of noninfectious renal mixed cryoglobulinemic GN.J Am Soc Nephrol2016;27:1213-24 PMCID:PMC4814186

[98] Nasr SH,Reddy BS,Swidler MA.Dysproteinemia, proteinuria, and glomerulonephritis.Kidney Int2006;69:772-5

[99] Rother U,Flad HD.Bithermic complement activation in cryoglobulinaemic serum.Eur J Clin Invest1972;2:59-65

[100] Linscott WD.The complement system in cryoglobulinaemia. Interaction with immunoglobulins and lipoproteins.Clin Exp Immunol1975;21:510-9 PMCID:PMC1538309

[101] Naish PF,Barratt J.Classical pathway complement activation in association with paraproteinaemia.Immunology1977;33:517-21 PMCID:PMC1445388

[102] Stasio E, Bizzarri P, Casato M, Galtieri A, Fiorilli M, Pucillo LP. Cl- regulates cryoglobulin structure: a new hypothesis for the physiopathological mechanism of temperature non-dependent cryoprecipitation.Clin Chem Lab Med2004;42:614-20

[103] Di Stasio E,Bove M.Analysis of the dynamics of cryoaggregation by light-scattering spectrometry.Clin Chem Lab Med2003;41:152-8

[104] Strait RT,Mahler A.IgG1 protects against renal disease in a mouse model of cryoglobulinaemia.Nature2015;517:501-4 PMCID:PMC4342786

[105] Sargur R,Egner W.Cryoglobulin evaluation: best practice?.Ann Clin Biochem2010;47:8-16

[106] Grey HM.Cryoimmunoglobulins.Semin Hematol1973;10:87-112

[107] Qi M,Schifferli JA.A calcium-dependent cryoglobulin IgM kappa/polyclonal IgG.J Immunol1992;149:2345-51

[108] Rosa FG, Agnello V. Observations on cryoglobulin testing: I. The association of cryoglobulins containing rheumatoid factors with manifestation of cryoglobulinemic vasculitis.J Rheumatol2009;36:1953-5

[109] Garcia-Bragado F,Navarro C,Bonaventura I.Peripheral neuropathy in essential mixed cryoglobulinemia.Arch Neurol1988;45:1210-4

[110] Tredici G,Cavaletti G,Crespi V.Sural nerve bioptic findings in essential cryoglobulinemic patients with and without peripheral neuropathy.Clin Neuropathol1992;11:121-7

[111] Cavaletti G,Crespi V,Marmiroli P.A clinico-pathological and follow up study of 10 cases of essential type II cryoglobulinaemic neuropathy.J Neurol Neurosurg Psychiatry1990;53:886-9 PMCID:PMC488251

[112] Collins MP.The vasculitic neuropathies: an update.Curr Opin Neurol2012;25:573-85

[113] Cacoub P,Domont F,Saadoun D.Cryoglobulinemia vasculitis.Am J Med2015;128:950-5

[114] D'Amico G,Ferrario F.Renal involvement in essential mixed cryoglobulinemia.Kidney Int1989;35:1004-14

[115] Javaugue V,Jaffer Sathick I.The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis.Kidney Int2022;102:382-94

[116] Beddhu S,Johnson JP.The clinical and morphologic spectrum of renal cryoglobulinemia.Medicine2002;81:398-409

[117] Sinico RA,Sabadini E,Castiglione A.Identification of glomerular immune deposits in cryoglobulinemia glomerulonephritis.Kidney Int1988;34:109-16

[118] Terrier B.Cryoglobulinemia vasculitis: an update.Curr Opin Rheumatol2013;25:10-8

[119] Cacoub P,Ghillani P.Extrahepatic manifestations of chronic hepatitis C.Arthritis Rheum1999;42:2204-12

[120] Dammacco R,Kivelä TT.The spectrum of ocular manifestations in patients with Waldenström's macroglobulinemia.Ocul Immunol Inflamm2022;30:1659-68

[121] Terrier B,Marie I.Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey.Blood2012;119:5996-6004

[122] Wener MH,Morishima C.Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia.Arthritis Rheum2004;50:2305-8

[123] Ferri C,Zignego AL.ISG-EHCV coauthorsInternational diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement.Autoimmun Rev2016;15:1145-60

[124] Ferri C,Giuggioli D.Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer.World J Hepatol2015;7:327-43 PMCID:PMC4381161

[125] Giuggioli D,Lumetti F,Ferri C.Cryoglobulinemic vasculitis and skin ulcers. Our therapeutic strategy and review of the literature.Semin Arthritis Rheum2015;44:518-26

[126] Gorevic PD,Levo Y.Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients.Am J Med1980;69:287-308

[127] Monti G,Invernizzi F.Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease..QJM1995;88:115-26

[128] Sansonno D.Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations.Lancet Infect Dis2005;5:227-36

[129] Ferri C.Mixed cryoglobulinemia.Orphanet J Rare Dis2008;3:25 PMCID:PMC2569912

[130] De Vita S,Isola M.A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.Arthritis Rheum2012;64:843-53

[131] Zaltron S,Liberini P.High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia.Ital J Gastroenterol Hepatol1998;30:391-5

[132] Gemignani F,Alfieri S.Clinical spectrum of cryoglobulinaemic neuropathy.J Neurol Neurosurg Psychiatry2005;76:1410-4 PMCID:PMC1739369

[133] Ferri C,Cirafisi C.Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations.J Rheumatol1992;19:889-95

[134] Feldman L,Li Y.Neurologic manifestations associated with cryoglobulinemia: a single center experience.J Neurol Sci2019;398:121-7

[135] Rossi D,Fenoglio R.Cryoglobulinemic glomerulonephritis: clinical presentation and histological features, diagnostic pitfalls and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy.Minerva Med2021;112:162-74

[136] Matignon M,Colombat M.Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection.Medicine2009;88:341-8

[137] Coliche V,Laville M.Predictive factors of renal involvement in cryoglobulinaemia: a retrospective study of 153 patients.Clin Kidney J2019;12:365-72 PMCID:PMC6543974

[138] Tarantino A,Banfi G.Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis.Kidney Int1995;47:618-23

[139] Roccatello D,Giachino O.Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis.Am J Kidney Dis2007;49:69-82

[140] Usuda H,Naito M.Crystalglobulin-induced vasculopathy accompanying ischemic intestinal lesions of a patient with myeloma.Pathol Int1996;46:165-70

[141] Terrier B,Cluzel P.Presentation and prognosis of cardiac involvement in hepatitis C virus-related vasculitis.Am J Cardiol2013;111:265-72

[142] Ali MA,Linzie BM,Wetmore JB.Myopericarditis in a patient with hepatitis C and cryoglobulinemic renal disease.Clin Case Rep2017;5:616-20 PMCID:PMC5412876

[143] Amital H,Naparstek Y.Alveolar hemorrhage in cryoglobulinemia - an indicator of poor prognosis.Clin Exp Rheumatol2005;23:616-20

[144] Zackrison LH.Bronchiolitis obliterans organizing pneumonia associated with essential mixed cryoglobulinemia.Arthritis Rheum1993;36:1627-30

[145] Younossi Z,Henry L,Stepanova M.Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden.Gastroenterology2016;150:1599-608

[146] Ramos-Casals M,Brito-Zerón P.Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases.Semin Arthritis Rheum2006;36:189-96

[147] Galli M,Marson P.Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome.Autoimmun Rev2019;18:778-85

[148] Fermand JP,Dispenzieri A.Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications.Blood2018;132:1478-85

[149] Besada E,Koldingsnes W.Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review.Int J Hematol2013;97:800-3

[150] Payet J,Kavian N.Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature.Leuk Lymphoma2013;54:767-77

[151] Calabrese C,Martin D,Calabrese LH.Type 1 cryoglobulinemia: response to thalidomide and lenalidomide.J Clin Rheumatol2011;17:145-7

[152] Lin RJ,Zimmerman TM,Niewold TB.Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma.J Clin Rheumatol2010;16:90-1 PMCID:PMC3319139

[153] Leung N,Hutchison CA.Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant.Blood2012;120:4292-5

[154] Bridoux F,Hutchison CA.International Kidney and Monoclonal Gammopathy Research GroupDiagnosis of monoclonal gammopathy of renal significance.Kidney Int2015;87:698-711

[155] Leung N,Batuman V.The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.Nat Rev Nephrol2019;15:45-59 PMCID:PMC7136169

[156] Fermand JP,Kyle RA.International Kidney and Monoclonal Gammopathy Research GroupHow I treat monoclonal gammopathy of renal significance (MGRS).Blood2013;122:3583-90

[157] Motwani SS,Monga D,Lam AQ.American Society of Nephrology Onco-Nephrology ForumParaprotein-related kidney disease: glomerular diseases associated with paraproteinemias.Clin J Am Soc Nephrol2016;11:2260-72 PMCID:PMC5142064

[158] Dimopoulos MA,Nahi H.POLLUX InvestigatorsDaratumumab, lenalidomide, and dexamethasone for multiple myeloma.N Engl J Med2016;375:1319-31

[159] Milani P,Curci P.Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function.Blood Adv2020;4:1321-4 PMCID:PMC7160273

[160] Kastritis E,Roussou M.Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance.Br J Haematol2021;193:113-8

[161] Sethi S,Rajkumar SV.Spectrum of manifestations of monoclonal gammopathy-associated renal lesions.Curr Opin Nephrol Hypertens2016;25:127-37

[162] Talamo G,Tricot G,Zangari M.Response to bortezomib in refractory type I cryoglobulinemia.Am J Hematol2008;83:883-4

[163] Spizzo G,Gunsilius E.Bortezomib for the treatment of refractory type-1 cryoglobulinaemia.Br J Haematol2010;150:235-7

[164] Ramirez GA,Salmaggi C.Bortezomib in type I cryoglobulinemic vasculitis: are we acting too late?.Intern Med2015;54:1119-23

[165] Ar M, Soysal T, Hatemi G, Salihoglu A, Yazici H, Ulku B. Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma.Ann Hematol2005;84:609-13

[166] Sampson A.The cutting edge: thalidomide for type 1 cryoglobulinemic vasculopathy.Arch Dermatol2006;142:972-4

[167] Callander NS,Adekola K.NCCN guidelines® insights: multiple myeloma, version 3.J Natl Compr Canc Netw2022;20:8-19

[168] Dimopoulos MA,Terpos E.Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up^†.Ann Oncol2021;32:309-22

[169] Castillo JJ,Branagan AR.Consensus treatment recommendations from the tenth international workshop for waldenström macroglobulinaemia.Lancet Haematol2020;7:e827-37

[170] Terpos E,Hajek R.Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.Blood Cancer J2021;11:40 PMCID:PMC7891472

[171] Moreau P,San Miguel J.Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.Lancet Oncol2021;22:e105-18

[172] Chu D,Gladstone DE.Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab.Rheumatol Int2007;27:1173-5

[173] Dimopoulos MA,Kyrtsonis MC.Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.J Clin Oncol2007;25:3344-9

[174] Dimopoulos MA,Gavriatopoulou M.Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European myeloma network (EMN).Blood2013;122:3276-82

[175] Dimopoulos MA,Trotman J.Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia.N Engl J Med2018;378:2399-410

[176] Leblond V,Advani R.Treatment recommendations from the Eighth International Workshop on Waldenström's macroglobulinemia.Blood2016;128:1321-8

[177] Gertz MA.Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.Am J Hematol2012;87:503-10

[178] Saadoun D,Hermine O.Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma.Arthritis Care Res2013;65:643-7

[179] Perez-Alamino R.Non-infectious cryoglobulinemia vasculitis (CryoVas): update on clinical and therapeutic approach.Curr Rheumatol Rep2014;16:420

[180] Martin M,Fornecker LM,Martin T.Bendamustine conditioning for refractory type I cryoglobulinemia.Joint Bone Spine2016;83:591-2

[181] Tedeschi A,Rizzi R.Diagnostic framing of IgM monoclonal gammopathy: focus on Waldenström macroglobulinemia.Hematol Oncol2019;37:117-28

[182] Treon SP,Meid K.Ibrutinib in previously treated Waldenström's macroglobulinemia.N Engl J Med2015;372:1430-40

[183] Ghobrial IM,Gertz M.Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.Am J Hematol2014;89:237-42

[184] Treon SP,Meid K.Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.Blood2014;124:503-10

[185] Treon SP,Branagan AR.Thalidomide and rituximab in Waldenstrom macroglobulinemia.Blood2008;112:4452-7 PMCID:PMC2597120

[186] Hunter ZR,Yang G.The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.Blood2014;123:1637-46

[187] Treon SP,Yang G.MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.N Engl J Med2012;367:826-33

[188] Goglin S.Current treatment of cryoglobulinemic vasculitis.Curr Treat Options Rheum2016;2:213-24

[189] Padmanabhan A,Aqui N.Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue.J Clin Apher2019;34:171-354

[190] Yang CH,Churchill WH.Long-term plasmapheresis in conjunction with thalidomide and dexamethasone for the treatment of cutaneous ulcers and neovascular glaucoma in recalcitrant type I cryoglobulinemia.JAMA Dermatol2014;150:426-8

[191] Nehme-Schuster H,Pasquali JL.Rituximab inefficiency during type I cryoglobulinaemia.Rheumatology2005;44:410-1

[192] Ghobrial IM,Greipp PR.Eastern Cooperative Oncology GroupInitial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern cooperative oncology group study.Cancer2004;101:2593-8

[193] Treon SP,Hunter Z,Tournhilac O.Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.Ann Oncol2004;15:1481-3

[194] Shaikh A,Fidler ME,Leung N.Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.Clin Exp Nephrol2008;12:292-5

[195] Mazzi G,Zucco M,Pomes A.Plasma-exchange in chronic peripheral neurological disorders.Int J Artif Organs1999;22:40-6

[196] Sinico RA,Fiorini G.Plasma exchange in the treatment of essential mixed cryoglobulinemia nephropathy. Long-term follow up.Int J Artif Organs1985;8 Suppl 2:15-8

[197] L'Abbate A,Caccamo A.Long term effects of cryoapheresis and cytostatic treatment in essential mixed cryoglobulinemia.Int J Artif Organs1985;8:19-22

[198] Rockx MA.Plasma exchange for treating cryoglobulinemia: a descriptive analysis.Transfus Apher Sci2010;42:247-51

[199] Guillevin L.Indications of plasma exchanges for systemic vasculitides.Ther Apher Dial2003;7:155-60

[200] Stone MJ.Evidence-based focused review of management of hyperviscosity syndrome.Blood2012;119:2205-8

[201] Stone MJ.Waldenström's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia.Clin Lymphoma Myeloma2009;9:97-9

[202] Treon SP.How I treat Waldenström macroglobulinemia.Blood2009;114:2375-85

[203] Zignego AL,Pileri SA,Bianchi FB.Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infectionExtrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach.Dig Liver Dis2007;39:2-17

[204] Pouchelon C,Emmi G.Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: data from a European collaborative study and review of the literature.Autoimmun Rev2022;21:103034

[205] Dammacco F,Russi S.Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis.Clin Exp Med2019;19:1-21

[206] Monti G,Rinaldi G,Gomitoni A.Colchicine in the treatment of mixed cryoglobulinemia.Clin Exp Rheumatol1995;13:S197-9

[207] Ferri C,Mazzaro C.Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.Autoimmun Rev2011;11:48-55

[208] Sneller MC,Langford CA.A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.Arthritis Rheum2012;64:835-42 PMCID:PMC3243106

[209] Specks U,Seo P.RAVE-ITN Research GroupEfficacy of remission-induction regimens for ANCA-associated vasculitis.N Engl J Med2013;369:417-27

[210] Zaja F,Fuga G.Rituximab for the treatment of type II mixed cryoglobulinemia.Haematologica2002;46:2252-64

[211] Arzoo K,Liebman HA.Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).Ann Rheum Dis2002;61:922-4 PMCID:PMC1753910

[212] Sansonno D,Lauletta G,Boiocchi M.Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20.Blood2003;101:3818-26

[213] Vita S, Quartuccio L, Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives.Dig Liver Dis2007;39:S122-8

[214] Cavallo R,Menegatti E,Napoli F.Rituximab in cryoglobulinemic peripheral neuropathy.J Neurol2009;256:1076-82

[215] Dammacco F,Lauletta G.Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.Blood2010;116:343-53

[216] Petrarca A,Caini P.Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.Blood2010;116:335-42

[217] Quartuccio L,Mansutti E.Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia.Clin Exp Rheumatol2010;28:84-7

[218] Quartuccio L,Romano G.Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.Rheumatology2006;45:842-6

[219] Roccatello D,Rossi D.Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.Clin Rev Allergy Immunol2008;34:111-7

[220] Roccatello D,Rossi D.Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.Nephrol Dial Transplant2004;19:3054-61

[221] Saadoun D,Sene D,Karras A.Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.Ann Rheum Dis2008;67:1431-6

[222] Terrier B,Kaplanski G.Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French autoimmunity and rituximab registry.Arthritis Care Res2010;62:1787-95

[223] Visentini M,Petrarca A.A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection.Autoimmun Rev2011;10:714-9

[224] Zaja F,Mazzaro C.Efficacy and safety of rituximab in type II mixed cryoglobulinemia.Blood2003;101:3827-34

[225] Visentini M,Veneziano ML.Efficacy of low-dose rituximab for mixed cryoglobulinemia.Clin Immunol2007;125:30-3

[226] Roccatello D,Baldovino S.Improved (4 Plus 2) Rituximab protocol for severe cases of mixed cryoglobulinemia: a 6-year observational study.Am J Nephrol2016;43:251-60

[227] Bryce AH,Kyle RA.Response to rituximab in patients with type II cryoglobulinemia.Clin Lymphoma Myeloma2006;7:140-4

[228] Wink F,Jansen TL.Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature.Clin Rheumatol2011;30:293-300

[229] Terrier B,Launay D.Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey.Autoimmun Rev2014;13:630-4

[230] Visentini M,Colantuono S.Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review.Autoimmun Rev2015;14:889-96

[231] Foessel L,Blaison G.Clinical spectrum, treatment, and outcome of patients with type II mixed cryoglobulinemia without evidence of hepatitis C infection.J Rheumatol2011;38:716-22

[232] Terrier B,Sène D.Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.Arthritis Rheum2009;60:2531-40

[233] Zignego AL,Ferri C.ISG-EHCVInternational therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement.Autoimmun Rev2017;16:523-41

[234] Ramos-Casals M,Ferri C.International Study Group of Extrahepatic Manifestations related to HCV (ISG-EHCV)Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.J Hepatol2017;66:1282-99

[235] Schwartz J,Aqui N.Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the seventh special issue.J Clin Apher2016;31:149-338

[236] Naciri Bennani H,Terrec F.Cryoglobulinemia and double-filtration plasmapheresis: Personal experience and literature review.Ther Apher Dial2023;27:159-69 PMCID:PMC10084379

[237] Evans TW,Shortland JR,Brown CB.Acute renal failure in essential mixed cryoglobulinemia: precipitation and reversal by plasma exchange.Clin Nephrol1984;21:287-93

[238] Puisset F,Kamar N.Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.Br J Clin Pharmacol2013;76:734-40 PMCID:PMC3853532

[239] Ramos-Casals M.Extrahepatic manifestations in patients with chronic hepatitis C virus infection.Curr Opin Rheumatol2005;17:447-55

[240] Mukhtyar C,Cid MC.European Vasculitis Study GroupEULAR recommendations for the management of primary small and medium vessel vasculitis.Ann Rheum Dis2009;68:310-7

[241] Argyropoulou OD,Chatzis L.Cryoglobulinemic vasculitis in primary Sjögren's syndrome: clinical presentation, association with lymphoma and comparison with hepatitis C-related disease.Semin Arthritis Rheum2020;50:846-53

[242] Basse G,Kamar N.Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients.Transplantation2005;80:1560-4

[243] Cacoub P,Saadoun D,Sene D.Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?.Ann Rheum Dis2008;67:283-7

[244] Basile U,Napodano C.Biomarkers of minimal residual disease in rituximab-treated patients with mixed cryoglobulinemia.Biotechnol Appl Biochem2021;68:319-29

[245] Frankel AH,Winearls CG,Rees AJ.Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients.Q J Med1992;82:101-24

[246] Verdickt W.Plasmapheresis combined with corticosteroids and cyclophosphamide in mixed monoclonal cryoglobulinaemia.Acta Clin Belg1982;37:237-40

[247] McKenzie RG,Dawborn JK.Glomerulonephritis secondary to mixed polyclonal cryoglobulinaemia: response to immunosuppression and plasmapheresis.Aust N Z J Med1981;11:529-33

[248] Geltner D,Gorevic P.The effect of combination therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular involvement.Arthritis Rheum1981;24:1121-7

[249] Houwert DA,Struyvenberg A.Effect of plasmapheresis (PP), corticosteroids and cyclophosphamide in essential mixed polyclonal cryoglobulinaemia associated with glomerulonephritis.Proc Eur Dial Transplant Assoc1980;17:650-4

[250] Ferri C,Gremignai G.Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange.Nephron1986;43:246-53

[251] Bombardieri S,Paleologo G.Prolonged plasma exchange in the treatment of renal involvement in essential mixed cryoglobulinemia.Int J Artif Organs1983;6:47-50

[252] Ramunni A,Brescia P.Double-filtration plasmapheresis in the treatment of leg ulcers in cryoglobulinemia.J Clin Apher2008;23:118-22

[253] Auzerie V,Bussel A.Leg ulcers associated with cryoglobulinemia: clinical study of 15 patients and response to treatment.Arch Dermatol2003;139:391-3

[254] Chevalier K,Seror R,Nocturne G.Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone.Ann Rheum Dis2020;79:1257-9

[255] Saadoun D,Riviere S.Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: a pilot study.J Autoimmun2021;116:102577

[256] De Vita S,Salvin S.Sequential therapy with belimumab followed by rituximab in Sjogren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.Clin Exp Rheumatol2014;32:490-4

[257] Cohen C,Saidenberg-Kermanac'h N.Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis.Ann Rheum Dis2012;71:628-9

[258] Saadoun D,Joly F.Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.N Engl J Med2011;365:2067-77

[259] Genest DS,Dallaire G,Troyanov S.Obinutuzumab rescue in rituximab resistant mixed cryoglobulinemia.Kidney Int Rep2021;6:865-6 PMCID:PMC7938147

[260] Dutton K,Owen R.Resistant type II cryoglobulinaemic vasculitis successfully treated with bortezomib in a patient with SLE.BMJ Case Rep2019;12:e226083 PMCID:PMC6326268

[261] Castillo JJ,Meid K,Hunter ZR.Rituximab intolerance in patients with Waldenström macroglobulinaemia.Br J Haematol2016;174:645-8

[262] Ostojic P.Cryoglobulinemic vasculitis in systemic sclerosis successfully treated with mycophenolate mofetil.Rheumatol Int2014;34:145-7

[263] Desbois AC,Sène D.Rituximab-associated vasculitis flare: incidence, predictors, and outcome.J Rheumatol2020;47:896-902

[264] Li X,Dong M.Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma.Leuk Lymphoma2010;51:1678-85

[265] Marignani M,Cox MC.HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens.Dig Liver Dis2011;43:139-42

[266] Sy-Go JPT,Herrera Hernandez LP,Leung N.Rituximab-associated flare of cryoglobulinemic vasculitis.Kidney Int Rep2021;6:2840-9 PMCID:PMC8589694

[267] Sène D,Amoura Z,Cacoub P.Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.Arthritis Rheum2009;60:3848-55

[268] Bryce AH,Dispenzieri A.Natural history and therapy of 66 patients with mixed cryoglobulinemia.Am J Hematol2006;81:511-8

[269] Terrier B,Krastinova E.Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey.Ann Rheum Dis2013;72:374-80

[270] Saadoun D,Ghillani-Dalbin P,Piette JC.Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia.Arch Intern Med2006;166:2101-8

[271] Landau DA,Sene D,Saadoun D.Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy.J Rheumatol2010;37:615-21

[272] Eble V,Joly P.Long term outcome of patients with low level of cryoglobulin (<0.05g/L).Autoimmun Rev2016;15:440-6

[273] Invernizzi F,Cattaneo R.A long-term follow-up study in essential cryoglobulinemia.Acta Haematol1979;61:93-9

[274] Civita L, Zignego AL, Monti M, Longombardo G, Pasero G, Ferri C. Mixed cryoglobulinemia as a possible preneoplastic disorder.Arthritis Rheum1995;38:1859-60

[275] Ramos-Casals M,Garcia-Carrasco M.Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma.J Rheumatol2004;31:495-9

[276] Monti G,Saccardo F.Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias.Arch Intern Med2005;165:101-5

[277] Saadoun D,Calabrese LH.Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation.Rheumatology2007;46:1234-42

[278] Giordano TP,Landgren O.Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.JAMA2007;297:2010-7

[279] Artemova M,Ignatova T.Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy.Hepatology2017;65:1770-1

[280] Sollima S,Antinori S.Direct-acting antivirals and mixed cryoglobulinemia vasculitis: long-term outcome of patients achieving HCV eradication.Am J Gastroenterol2017;112:1753-4

[281] Saadoun D,Ferfar Y.Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis.Gastroenterology2017;153:49-52

[282] Saadoun D,Thibault V,Cacoub P.Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.Arthritis Rheum2006;54:3696-706

[283] Bonacci M,Mariño Z.Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure.Gastroenterology2018;155:311-15

[284] Banerjee D.Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.Aliment Pharmacol Ther2016;43:674-96

[285] Colantuono S,Del Padre M.Clinico-immunological outcomes of HCV-cured cryoglobulinemia: lower relapse rate with interferon-based than interferon-free therapy.Liver Int2021;41:70-5

[286] Scarpato S,Quartuccio L.Italian Group for the Study of Cryoglobulinaemia (GISC)Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis.Clin Exp Rheumatol2021;39:149-54

[287] Furer V,Heijstek MW.2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.Ann Rheum Dis2020;79:39-52